Holen Sie sich die Stockscreener-App
282.13
0.80%
-2.07
Schlusskurs vom Vortag:
$284.20
Offen:
$280
24-Stunden-Volumen:
319.95K
Relative Volume:
0.22
Marktkapitalisierung:
$46.08B
Einnahmen:
$2.86B
Nettoeinkommen (Verlust:
$780.66M
KGV:
59.77
EPS:
4.72
Netto-Cashflow:
$1.20B
1W Leistung:
-2.92%
1M Leistung:
-0.34%
6M Leistung:
+20.87%
1J Leistung:
+49.06%
1-Tages-Spanne:
$278.00
$283.53
1-Wochen-Bereich:
$278.00
$296.72
52-Wochen-Spanne:
$177.41
$296.72
Veeva Systems Inc Stock (VEEV) Company Profile
Firmenname
Veeva Systems Inc
Sektor
Branche
Telefon
925-452-6500
Adresse
4280 HACIENDA DRIVE, PLEASANTON, CA
Vergleichen Sie VEEV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VEEV
Veeva Systems Inc
|
282.00 | 46.88B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
55.40 | 10.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
92.21 | 8.54B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
57.72 | 11.03B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
35.80 | 6.17B | 906.14M | -52.62M | 89.62M | -0.3621 |
Veeva Systems Inc Stock (VEEV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-29 | Bestätigt | Needham | Buy |
| 2025-01-23 | Herabstufung | Goldman | Buy → Sell |
| 2024-12-20 | Eingeleitet | Stephens | Overweight |
| 2024-12-04 | Eingeleitet | Mizuho | Outperform |
| 2024-11-19 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-08 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2024-08-27 | Bestätigt | Citigroup | Buy |
| 2024-07-09 | Eingeleitet | BTIG Research | Buy |
| 2023-10-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-10-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-28 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Truist | Buy → Hold |
| 2023-02-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-04 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-06 | Eingeleitet | Cowen | Market Perform |
| 2022-12-02 | Bestätigt | Needham | Buy |
| 2022-10-31 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-10-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | Goldman | Buy |
| 2022-06-21 | Fortgesetzt | Guggenheim | Buy |
| 2022-03-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2022-01-07 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Fortgesetzt | Stifel | Buy |
| 2021-09-02 | Bestätigt | BofA Securities | Buy |
| 2021-09-02 | Bestätigt | JMP Securities | Mkt Outperform |
| 2021-09-02 | Bestätigt | Needham | Buy |
| 2021-09-02 | Bestätigt | UBS | Neutral |
| 2021-07-21 | Eingeleitet | Cowen | Outperform |
| 2021-03-31 | Hochstufung | UBS | Sell → Neutral |
| 2021-01-07 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2020-12-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-10-14 | Fortgesetzt | UBS | Sell |
| 2020-08-28 | Bestätigt | Needham | Buy |
| 2020-07-23 | Eingeleitet | FBN Securities | Outperform |
| 2020-07-07 | Eingeleitet | Stephens | Overweight |
| 2020-06-08 | Eingeleitet | Citigroup | Buy |
| 2020-05-29 | Bestätigt | Needham | Buy |
| 2020-04-13 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-14 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-11-27 | Bestätigt | Canaccord Genuity | Hold |
| 2019-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-08-28 | Bestätigt | Needham | Buy |
| 2019-06-07 | Eingeleitet | Goldman | Neutral |
| 2019-05-30 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2019-05-24 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-27 | Bestätigt | Needham | Buy |
Alle ansehen
Veeva Systems Inc Aktie (VEEV) Neueste Nachrichten
What are the technical indicators suggesting about Veeva Systems Inc.Financial News Planner For Consistent Profits - jammulinksnews.com
Veeva Systems Slides to 396th in Daily Trading Volume Despite AI-Driven Growth and Merck Partnership - AInvest
What is Veeva Systems Inc. company’s growth strategyAI Powered Planner Backed By Experts - jammulinksnews.com
Here's Why Veeva Systems (VEEV) is a Strong Growth Stock - Yahoo Finance
Wall Street Analysts See Veeva (VEEV) as a Buy: Should You Invest? - Yahoo Finance
How many analysts rate Veeva Systems Inc. as a “Buy”AI Powered Strategy For 2025 - jammulinksnews.com
What makes Veeva Systems Inc. stock price move sharplyReal Time Watchlist With Proven Results - jammulinksnews.com
Oppenheimer Considers Merck & Co. (MRK) Agreement as Strong Endorsement for Veeva’s Vault CRM - Yahoo.co
What are Veeva Systems Inc. company’s key revenue driversSwing Trade Opportunities From AI Tools - jammulinksnews.com
AI Stock With Unique Focus Joins Palantir, Nvidia On 3 Elite Lists - Investor's Business Daily
Survey Finds Medtechs Lack Confidence in Regulatory Data Quality - PR Newswire
Technical Heatmap Flags Veeva Systems Inc. for WatchFast Entry High Potential Stock Alerts Triggered - metal.it
Veeva Systems (NYSE:VEEV) Stock Performs Better Than Its Underlying Earnings Growth Over Last Year - 富途牛牛
Veeva Systems Inc. Shows Risk Reward Favoring UpsideFundamental Growth Stock Analysis Shows Strength - metal.it
Veeva Systems’ SWOT analysis: life sciences leader faces CRM stock battle - Investing.com
Published on: 2025-07-28 23:17:27 - metal.it
What catalysts could drive Veeva Systems Inc. stock higher in 2025Post Market Updates For Consistent Profits - jammulinksnews.com
EssilorLuxottica and Edwards Lifesciences: Accelerating Patient Access: How Technology Speeds Delivery of High-quality Medical Devices - Veeva
Thoughts on Veeva Vault CRM vs. Salesforce CRM for Biopharma - Veeva
Veeva Systems (VEEV) Surpassed Expectations in Q2 - Insider Monkey
When is Veeva Systems Inc. stock expected to show significant growthSkyrocketing returns - jammulinksnews.com
Is Veeva Systems Inc. stock overvalued or undervaluedInvest smarter with daily stock recommendations - jammulinksnews.com
Is it the right time to buy Veeva Systems Inc. stockCapitalize on emerging trends for profits - jammulinksnews.com
Does Veeva Systems Inc. stock perform well during market downturnsAchieve breakthrough gains with smart trades - jammulinksnews.com
How volatile is Veeva Systems Inc. stock compared to the marketCapitalize on momentum-driven stocks - jammulinksnews.com
VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait? - MSN
Is Veeva Systems Inc. a good long term investmentMassive profits - PrintWeekIndia
Investors Heavily Search Veeva Systems Inc. (VEEV): Here is What You Need to Know - MSN
Veeva Systems Inc. (VEEV) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
What drives Veeva Systems Inc. stock priceExponential wealth increase - PrintWeekIndia
Veeva Systems Inc. Stock Analysis and ForecastSky-high return potential - Autocar Professional
Veeva Systems (VEEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Veeva's Vault Vision: Can It Thrive After Parting With Salesforce? - The Globe and Mail
Veeva Systems stock hits 52-week high at $291.71 - Investing.com
Speed, Scale, and Connectivity: Teva’s New Standard for Medical Information - Veeva
What analysts say about Veeva Systems Inc. stockTurbocharged investment results - jammulinksnews.com
Veeva Vs. Salesforce: Which Life Sciences CRM Stock Is The Better Buy? - Barchart.com
Veeva vs. Salesforce: Which Life Sciences CRM Stock Is the Better Buy? - The Globe and Mail
Veeva OpenData and Veeva Network Enable Coordinated Customer Engagement for Boehringer Ingelheim - Veeva
Boehringer Ingelheim Standardizes Customer Data with Veeva Across 100 Countries - AInvest
Boehringer Ingelheim adopts Veeva data solutions across 100+ countries By Investing.com - Investing.com Canada
Top 20 Pharma Giant Boehringer Ingelheim Adopts Veeva Platform Across 100+ Countries for AI-Ready Future - Stock Titan
Veeva Systems (VEEV) Gets a Buy from Raymond James - The Globe and Mail
Best Statistical Healthcare Participant Recruitment - openPR.com
Finanzdaten der Veeva Systems Inc-Aktie (VEEV)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):